The story has been updated to include comments from a conference call.

NEW YORK (GenomeWeb News) – Exact Sciences said today that revenues in the third quarter came in flat year over year as the firm matched consensus Wall Street estimates on the top and bottom line.

For the three months ended Sept. 30, revenues of $1.0 million were even with the year-ago figure and matched the average analyst estimate of $1.0 million. All revenues came from licensing fees both in the most recently concluded quarter and the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.